Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

GEMFIBROZIL CRS (5 MG)

GEMFIBROZIL CRS (5 MG)

25812-30-0

DISCOVER
GEMFIBROZIL FOR SYSTEM SUITABILITY CRS (0.196 MG)

GEMFIBROZIL FOR SYSTEM SUITABILITY CRS (0.196 MG)

25812-30-0

DISCOVER
GLIMEPIRIDE CRS (110 MG)

GLIMEPIRIDE CRS (110 MG)

93479-97-1

DISCOVER
GLIMEPIRIDE FOR SYSTEM SUITABILITY CRS (0.012 MG)

GLIMEPIRIDE FOR SYSTEM SUITABILITY CRS (0.012 MG)

93479-97-1

DISCOVER
GLUTATHIONE CRS (10 MG)

GLUTATHIONE CRS (10 MG)

70-18-8

DISCOVER
LAMIVUDINE FOR SYSTEM SUITABILITY 1 CRS (10 MG)

LAMIVUDINE FOR SYSTEM SUITABILITY 1 CRS (10 MG)

134678-17-4

DISCOVER
MYCOPHENOLATE MOFETIL FOR PEAK IDENTIFICATION CRS (10 MG)

MYCOPHENOLATE MOFETIL FOR PEAK IDENTIFICATION CRS (10 MG)

128794-94-5

DISCOVER
NEVIRAPINE (ANHYDROUS) CRS (30 MG)

NEVIRAPINE (ANHYDROUS) CRS (30 MG)

129618-40-2

DISCOVER
NEVIRAPINE FOR PEAK IDENTIFICATION CRS (0.058 MG)

NEVIRAPINE FOR PEAK IDENTIFICATION CRS (0.058 MG)

129618-40-2

DISCOVER
NORETHISTERONE FOR SYSTEM SUITABILITY CRS (10 MG)

NORETHISTERONE FOR SYSTEM SUITABILITY CRS (10 MG)

68-22-4

DISCOVER
GLIPIZIDE IMPURITY C CRS (10 MG)

GLIPIZIDE IMPURITY C CRS (10 MG)

NA

DISCOVER
PAMIDRONATE DISODIUM PENTAHYDRATE CRS (10 MG)

PAMIDRONATE DISODIUM PENTAHYDRATE CRS (10 MG)

109552-15-0

DISCOVER